PFSA

Profusa, Inc. develops and commercializes biosensor technology for continuous tissue monitoring applications in medical and defense sectors. The privately-held biotechnology company, headquartered in South San Francisco, California, specializes in injectable biosensors that integrate with the body's tissue to provide real-time physiological data without the need for external wearable devices. Profusa's flagship Lumee Oxygen Platform utilizes bioengineered hydrogel sensors, smaller than a grain of rice, that measure tissue oxygen and other biomarkers continuously when paired with a wearable optical reader. The company's technology has received significant funding from the U.S. Defense Advanced Research Projects Agency (DARPA) and the Biomedical Advanced Research and Development Authority (BARDA) for applications in combat casualty care and infectious disease monitoring. In 2021, Profusa received a Breakthrough Device Designation from the FDA for its tissue oxygen monitoring system intended for use in peripheral artery disease patients. The company operates research and development facilities in California and maintains partnerships with academic institutions and government agencies. Profusa employs approximately 50 people and focuses on advancing its sensor platform through clinical trials while exploring applications in chronic disease management, trauma care, and pharmaceutical development. The company continues to pursue regulatory approvals for commercial deployment of its biosensor technology.